Skip to main content
. 2021 Oct 30;22(21):11791. doi: 10.3390/ijms222111791

Figure 2.

Figure 2

Quantitative immunohistochemistry of brains from hAPPsl×hQC mice after treatment with PQ912 (Varoglutamstat), a monoclonal pGlu-Aβ antibody (m6-Ab) or in combination for 16 weeks. (a) K17 stains pGlu3-Aβ, (b) 82E1 stains the Aβ N-terminus starting with amino acid 1 [Aβ(1–x)]. Significant differences between isotype control and baseline (t-test) indicate a development of Aβ pathology over the treatment period. In comparison to the isotype control, nominal lower mean Aβ staining was found in case of all treatments. The combination treatment resulted in significantly reduced staining for pGlu3-Aβ. Kruskal–Wallis test for group comparison (top line p-value) with Dunn’s test for post-hoc comparison with isotype control (p-values above bars) (*—p < 0.05, **—p < 0.01, ***—p < 0.001).